[ad_1]
The study will show whether different vaccines, in this case AstraZeneca and Pfizer-BioNTech, can be used together to address the challenges of vaccine delivery more flexibly.
Jonathan Van-Tam, deputy chief medical officer for the UK government, said the study would provide a better understanding of the use of vaccines to combat COVID-19.
“Given the unavoidable challenges of vaccinating a large portion of the population against COVID-19 and the potential disruption to global supply, the study findings could help create a more flexible immunization schedule,” Van-Tam said.
“It is also possible that by combining the vaccines, the immune response can be enhanced and the higher antibody levels last longer,” he added.
The 13-month study will compare the different doses of the AstraZeneca and Pfizer-BioNTech vaccines at 4 and 12 weeks between the first and second vaccinations.
Oxford University professor Matthew Snape called the study “extremely exciting” because it would provide “critical information for vaccination in the UK and around the world.”
No part of this publication may be reproduced without the written permission of ELTA.
[ad_2]
